前往化源商城

American Heart Journal 2013-11-01

Incidence of atrial fibrillation in a population with impaired glucose tolerance: The contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial

Roberto Latini, Lidia Staszewsky, Jie-Lena Sun, M. Angelyn Bethel, Marcello Disertori, Steven M. Haffner, Rury R. Holman, Futien Chang, Thomas D. Giles, Aldo P. Maggioni, Guy E.H.M. Rutten, Eberhard Standl, Laine Thomas, Gianni Tognoni, Robert M. Califf, John J.V. McMurray

文献索引:Am. Heart J. 166(5) , 935-40.e1, (2013)

全文:HTML全文

摘要

Background The role of dysglycemia as an additional risk factor for atrial fibrillation (AF) is controversial. Therefore, it was of interest to assess risk factors for incident AF in a large, representative population of patients with cardiovascular risk factors and impaired glucose tolerance but not overt diabetes in NAVIGATOR.

相关化合物

结构式 名称/CAS号 全部文献
那格列奈 结构式 那格列奈
CAS:105816-04-4
l-缬氨酸 结构式 l-缬氨酸
CAS:72-18-4
L-苯丙氨酸 结构式 L-苯丙氨酸
CAS:63-91-2
缬沙坦 结构式 缬沙坦
CAS:137862-53-4
那格列奈相关物质C 结构式 那格列奈相关物质C
CAS:105816-06-6